Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 9/20 | 0.62 |
| ▸ | HTR3A | P46098 | 4/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.57 |
| ▸ | HTR3B | O95264 | 3/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5229788 | 0.93 | ADRB1 (0.55) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| Hydrochloric Acid SCHEMBL381874 | 0.91 | ADRB1 (0.53) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL23772144 | 0.89 | ADRB1 (0.48) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| Tert-Butyl Formate SCHEMBL28331831 | 0.86 | ADRB1 (0.47) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL20178041 | 0.85 | HSD11B1 (0.57) | ALDH1A1KDM4ELMNAHSD11B1USP2 | |
| SCHEMBL12088780 | 0.85 | ADRB1 (0.58) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL18308985 | 0.84 | L3MBTL3 (0.53) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL24123997 | 0.83 | CYP2D6 (0.63) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL5570604 | 0.82 | ADRB1 (0.77) | ADRB1HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL14384537 | 0.82 | ADRB1 (0.55) | ADRB1HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059950-A | Compounds with proteasome agonistic activity, preparation method and application thereof | 浙大城市学院 | 2026-05-19 | — | — | CN | disclosed |
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| EP-4371982-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-3583096-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-0974573-A1 | PHENYLPROPENONE COMPOUNDS AND MEDICINES CONTAINING THE SAME | Kabushiki Kaisha Yakult Honsha (JP) | 2000-01-26 | — | — | EP | disclosed |
| EP-0278008-B1 | TAURINE TYPE COMPOUNDS | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1993-01-20 | — | — | EP | disclosed |
| EP-0327912-B1 | N,N-DISUBSTITUTED PIPERAZINES | BASF Aktiengesellschaft (DE) | 1992-04-08 | — | — | EP | disclosed |
| US-4935426-A | FUNGICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1990-06-19 | — | — | US | disclosed |
| US-4870078-A | TAURINE-TYPE COMPOUNDS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1989-09-26 | — | — | US | disclosed |
| EP-0327912-A1 | N,N-disubstituted piperazines | BASF Aktiengesellschaft (DE) | 1989-08-16 | — | — | EP | disclosed |
| EP-0278008-A1 | TAURINE TYPE COMPOUNDS | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-08-17 | — | — | EP | disclosed |
| EP-0114374-B1 | SUBSTITUTED 4-AMINOMETHYLENE CHROMANS OR CHROMENES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINES | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
| US-4563458-A | CIRCULATORY SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
| EP-0114374-A1 | Substituted 4-aminomethylene chromans or chromenes, process for their preparation and their use in medicines | BAYER AG (DE) | 1984-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | ADRB1 1589/4885HTR3A 916/4885HTR3E 836/4885 |
| US-20230382909-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | ADRB1 853/4885HTR3A 2220/4885HTR3E 3034/4885 |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | ADRB1 853/4885HTR3A 2220/4885HTR3E 3034/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | ADRB1 423/4885HTR3A 2526/4885HTR3E 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.